GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$38.96 USD
-0.25 (-0.64%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $38.98 +0.02 (0.05%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$38.96 USD
-0.25 (-0.64%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $38.98 +0.02 (0.05%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Zacks News
Pfizer (PFE) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Higher sales of Pfizer's (PFE) key brands, Eliquis, Ibrance and Inlyta, in the Biopharma segment are likely to have made up for lower sales in the Upjohn group in the third quarter.
5 Big Pharma/Biotech Stocks Set to Trump Q3 Earnings Estimates
by Zacks Equity Research
Let us take a look at some drug/biotech stocks including Glaxo (GSK) and Merck (MRK) that are poised to beat on earnings for the third quarter.
Sanofi's mRNA Vaccine for Coronavirus to Enter Clinical Stage
by Zacks Equity Research
Sanofi (SNY) and Translate Bio select coronavirus vaccine candidate MRT5500 for clinical development, based on its promising pre-clinical data. A clinical study is anticipated by this year-end.
Merck's Keytruda Gets FDA Nod for Expanded Use in Lymphoma
by Zacks Equity Research
The FDA approves Merck's (MRK) Keytruda for the treatment of adult patients with relapsed or refractory cHL who progress after frontline therapy.
The Zacks Analyst Blog Highlights: JNJ, Eli Lilly, Merck, AbbVie and GSK
by Zacks Equity Research
The Zacks Analyst Blog Highlights: JNJ, Eli Lilly, Merck, AbbVie and GSK
Do J&J's Q3 Results Indicate a Sales Recovery for Big Pharma?
by Kinjel Shah
Investors typically look at J&J's (JNJ) results for signals regarding how the rest of the big drugmakers will fare.
Sanofi's Dupixent Meets All Goals in Asthma Study for Children
by Zacks Equity Research
Sanofi's (SNY) blockbuster drug Dupixent meets primary as well as all key secondary goals in a late-stage study for treating moderate-to-severe asthma in children aged six-11 years.
Pharma Stock Roundup: LLY, AZN, PFE, GSK Progress on Coronavirus Programs
by Kinjel Shah
Lilly (LLY), Pfizer (PFE) and AstraZeneca (AZN) provide updates on their coronavirus vaccine/treatment programs.
Vir Biotech, Glaxo Begin Phase III Study on Coronavirus Therapy
by Zacks Equity Research
Vir Biotechnology (VIR) and British partner Glaxo announce the global expansion of their COMET-ICE study on the COVID-19 antibody candidate VIR-7831 to phase III.
SpringWorks Inks Deal With Pfizer for Nirogacestat Combo
by Zacks Equity Research
SpringWorks (SWTX) inks a collaboration deal with Pfizer to evaluate nirogacestat along with the latter's BCMA-targeted therapy PF-06863135 for treating relapsed/refractory multiple myeloma. Stock up.
Pharma Stock Roundup: FDA Approves New Uses of PFE, JNJ & GSK's Drugs
by Kinjel Shah
New indications of Glaxo's (GSK) Nucala J&J's (JNJ) Simponi Aria and Pfizer's (PFE) Xeljanz get FDA's nod.
Glaxo Gets FDA Nod for Nucala for Hypereosinophilic Syndrome
by Zacks Equity Research
Glaxo's (GSK) Nucala becomes the first and only targeted biologic treatment to be approved for hypereosinophilic syndrome (HES), a rare disease caused by eosinophilic inflammation.
The Zacks Analyst Blog Highlights: JNJ, Pfizer, AstraZeneca, Sanofi and GSK
by Zacks Equity Research
The Zacks Analyst Blog Highlights: JNJ, Pfizer, AstraZeneca, Sanofi and GSK
Verona (VRNA) Initiates Pivotal COPD Studies on Ensifentrine
by Zacks Equity Research
Verona Pharma (VRNA) is developing twice-daily nebulized formulation of ensifentrine as potential maintenance treatment for COPD.
Pharma Stock Roundup: J&J's Coronavirus Vaccine in Phase III, Other Updates
by Kinjel Shah
J&J (JNJ) becomes the fourth company to start a phase III study on its coronavirus vaccine candidate. CHMP recommends approval of several drugs.
Sanofi/Glaxo to Supply 70M Coronavirus Vaccine Doses in Canada
by Zacks Equity Research
Sanofi's (SNY) recombinant protein-based technology is being combined with Glaxo's pandemic adjuvant technology to develop an adjuvanted COVID-19 vaccine.
4 Biotechs That Have More Than Doubled Thanks to Coronavirus
by Kinjel Shah
Stocks of several small biotech companies more than double so far this year as they taste success in their efforts to make a vaccine/medicine for treating COVID-19.
Glaxo's Zejula Gets Positive CHMP View for First-Line Setting
by Zacks Equity Research
The CHMP's favorable response recommends the regulatory nod for GlaxoSmithKline's (GSK) Zejula as the first-line maintenance treatment of ovarian cancer patients regardless of the biomarker status.
Sanofi/Glaxo to Supply 300M Coronavirus Vaccine Doses in EU
by Zacks Equity Research
Sanofi (SNY) recombinant protein-based technology is being combined with Glaxo's (GSK) pandemic adjuvant technology to develop an adjuvanted COVID-19 vaccine.
GlaxoSmithKline (GSK) Stock Moves -0.53%: What You Should Know
by Zacks Equity Research
GlaxoSmithKline (GSK) closed at $39.26 in the latest trading session, marking a -0.53% move from the prior day.
Mylan/Pfizer's Upjohn Unit Merger on Track to Close in Q4
by Zacks Equity Research
The pending merger of Pfizer's (PFE) Upjohn unit with Mylan (MYL) is on track to close in the fourth quarter of 2020 as almost all necessary regulatory clearances are in place.
Gilead's Oncology Drug Gets Breakthrough Therapy Designation
by Zacks Equity Research
Gilead's (GILD) magrolimab obtains Breakthrough Therapy designation in the United States for the treatment of newly-diagnosed myelodysplastic syndrome (MDS).
The Zacks Analyst Blog Highlights: Walmart, Oracle, Sanofi, Amazon, GlaxoSmithKline and CVS Health
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Walmart, Oracle, Sanofi, Amazon, GlaxoSmithKline and CVS Health
Top Analyst Reports for Walmart, Oracle & Sanofi
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Walmart (WMT), Oracle (ORCL) and Sanofi (SNY).
Sanofi's Dupixent Gets Breakthrough Status for New Indication
by Zacks Equity Research
Sanofi's (SNY) blockbuster drug, Dupixent gets Breakthrough Therapy designation from the FDA as potential treatment for eosinophilic esophagitis.